Utilized for ischemic stroke and myocardial infarction to target platelet activity and support vascular health.
Mechanism of Action
Clopidogrel is a prodrug that must be metabolized to an active form. It irreversibly inhibits the binding of adenosine diphosphate to its platelet P2Y12 receptor, preventing the activation of the GPIIb/IIIa complex and subsequent platelet aggregation.
Route of Administration
Oral
Onset Time
2 hours
Duration
7–10 days (irreversible effect)
Contraindications
Active pathological bleeding, Hypersensitivity to clopidogrel, Severe hepatic impairment
Severe Adverse Events
Thrombotic thrombocytopenic purpura, Severe gastrointestinal hemorrhage, Intracranial bleeding — requires immediate medical attention
Common Side Effects
Bruising, Minor bleeding, Dyspepsia
Uncommon Side Effects
Diarrhea, Abdominal pain, Rash
Drug Interactions
Aspirin, Warfarin, Omeprazole, NSAIDs, Alcohol
Pregnancy Safety Warnings
FDA Category B: No evidence of fetal risk. Breastfeeding: Excretion in milk is unknown; not recommended.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Information related to Clopidogrel is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
